A Phase II Study Of Sunitinib And Low Dose Metronomic Cyclophosphamide In Advanced Renal Cell Cancer.
Latest Information Update: 18 Jun 2019
At a glance
- Drugs Cyclophosphamide (Primary) ; Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms SUN-CYCL
- 15 Jun 2019 Status changed from recruiting to completed.
- 21 Jun 2012 Companies added in the association field as reported by EudraCT.
- 07 Jun 2011 New trial record